<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6521">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860703</url>
  </required_header>
  <id_info>
    <org_study_id>LA37-1111</org_study_id>
    <nct_id>NCT01860703</nct_id>
  </id_info>
  <brief_title>Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects</brief_title>
  <official_title>A Double-Blind, Randomized, Crossover, Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, single-dose, double-blind, double-dummy, placebo and active
      controlled, four-period crossover study to evaluate the effect of deferiprone on QTc
      prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50
      mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-marketing study to evaluate the effect of deferiprone and deferiprone 3-O-glucuronide
      on QTc prolongation in healthy volunteers after administration of a single therapeutic (33
      mg/kg) and supratherapeutic (50 mg/kg) oral dose of deferiprone and moxifloxacin (Avelox®).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>To evaluate the effects of deferiprone on QT interval (QT) and heart rate corrected QT interval (QTc) duration in healthy volunteers as compared to the effects of placebo treatment from baseline to 24 hours post-dose.</measure>
    <time_frame>Baseline and at -0.75, -0.5, -0.25 pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The effects of deferiprone on QT interval will be measured using the following: the difference in change from baseline in Fridericia's QT corrected heart rate (dQTcF) between treatment and placebo (ddQTcF) at each postdose timepoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of adverse events in healthy subjects who received single therapeutic and supratherapeutic doses of deferiprone.</measure>
    <time_frame>Prior to dosing until 7 days +/- 1 day following dosing.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed based on the number of adverse events (AEs) experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the maximum observed plasma concentration (Cmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the serum drug concentration-QT relationship (i.e., time course of QT and QTc interval prolongation in relation to serum levels of deferiprone and deferiprone 3-O-glucuronide).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The relationship between dQTcF and serum concentration profiles will be derived from parameter values collected from baseline to 24 hours post-dose, such as Cmax and AUC for deferiprone and deferiprone 3-O-glucuronide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the difference between deferiprone and placebo changes in QTc from baseline to 24 hours post-dose.</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The difference between deferiprone and placebo changes in QTC from baseline to 24 hours post-dose will be assessed using Bazett's correction (ddQTcB) at each post-dose timepoint, through calculation of HR, QT, QTc, PR, RR, and QRS for each assessment time point for each treatment and morphological changes of ECG waveform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the maximum observed plasma concentration (Cmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to reach maximum observed plasma concentration (Tmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the area under the curve (AUC) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma decay half- life (t1/2)  of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half from serum deferiprone and serum deferiprone 3-O-glucuronide samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to reach maximum observed plasma concentration (Tmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the area under the curve (AUC) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma decay half-life (t1/2) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).</measure>
    <time_frame>Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half from serum deferiprone and serum deferiprone 3-O-glucuronide samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate any changed in standard 12-lead ECG results in healthy subjects who received single therapeutic and supratherapeutic doses of deferiprone.</measure>
    <time_frame>Prior to dosing until 7 days +/- 1 day following dosing.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed based on any changes in standard 12-lead ECG results.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A - Maximum Therapeutic Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets, deferiprone matching placebo tablets and one moxifloxacin matching placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B - Supratherapeutic Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets, and one moxifloxacin matching placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C - Placebo Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of deferiprone matching placebo tablets and one moxifloxacin matching placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm D - Positive Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of deferiprone matching placebo tablets and one 400 mg moxifloxacin tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <arm_group_label>Treatment Arm A - Maximum Therapeutic Dose</arm_group_label>
    <arm_group_label>Treatment Arm B - Supratherapeutic Dose</arm_group_label>
    <arm_group_label>Treatment Arm D - Positive Control</arm_group_label>
    <other_name>Ferriprox 500 mg tablets</other_name>
    <other_name>Deferiprone matching placebo tablets</other_name>
    <other_name>L1</other_name>
    <other_name>Moxifloxacin (Avelox®) 400 mg tablets</other_name>
    <other_name>Moxifloxacin matching placebo tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deferiprone matching placebo tablets</intervention_name>
    <arm_group_label>Treatment Arm A - Maximum Therapeutic Dose</arm_group_label>
    <arm_group_label>Treatment Arm C - Placebo Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin matching placebo tablet</intervention_name>
    <arm_group_label>Treatment Arm A - Maximum Therapeutic Dose</arm_group_label>
    <arm_group_label>Treatment Arm B - Supratherapeutic Dose</arm_group_label>
    <arm_group_label>Treatment Arm C - Placebo Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <arm_group_label>Treatment Arm D - Positive Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Healthy adult males or females, 18 - 45 years of age (inclusive).

          2. Body weight ≥ 50 kg.

          3. Body mass index (BMI) ≥ 19 and ≤ 32 kg/m2.

          4. Medically healthy with clinically insignificant screening results (e.g., laboratory
             profiles, medical history, vital signs, physical examination).

          5. Absolute neutrophil count (ANC) of &gt;1.5x109/L.

          6. 12-lead ECGs which have no clinically significant findings as judged by the Principal
             Investigator (PI) or the PI's designee at screening and check-in of each study
             period,including:

               1. Normal sinus rhythm (heart rate between 45 and 100 bpm);

               2. QTcF interval ≤ 450 msec;

               3. QRS interval ≤ 110 msec; and

               4. PR interval ≤ 220 msec.

          7. Subject must be capable of providing written informed consent, and must voluntarily
             consent to participate in the study.

          8. Willing to answer inclusion and exclusion criteria questionnaire at check-in.

        Main Exclusion Criteria:

          1. History or presence of significant respiratory, cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic,
             dermatologic,neurologic, or psychiatric disease.

          2. Disorders or surgery of the gastrointestinal tract which may interfere with drug
             absorption or may otherwise influence the PK of the investigational medicinal
             products (e.g. cholecystectomy, resections of the small or large intestine, febrile
             conditions, chronic diarrhea, chronic vomiting, endocrine disease, severe
             infections,acute inflammations, etc.).

          3. Presence of liver impairment: aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) above the normal reference range.

          4. Presence of significant kidney impairment: serum creatinine higher than the normal
             reference range.

          5. Allergy to band aids, adhesive dressing or medical tape.

          6. Clinically significant history or presence of ECG abnormalities such as second- or
             third-degree atrioventricular block; evidence, or family history, of prolonged QT
             syndrome.

          7. Sustained sitting systolic blood pressure of &lt;90 mmHg or &gt;140 mmHg, or diastolic
             blood pressure of &gt;95 mmHg at screening or check-in of Period 1.

          8. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone,
             moxifloxacin, iron chelators, or quinolone antibiotics.

          9. History or presence of:

               -  agranulocytosis;

               -  asthma;

               -  chronic bronchitis;

               -  diabetes;

               -  migraine;

               -  hypertension;

               -  hypotension;

               -  hypokalemia;

               -  seizures or epilepsy;

               -  anaemia.

         10. History or presence of alcoholism or drug abuse within the past 2 years.

         11. Used tobacco/nicotine-containing product for at least 3 months prior to the first
             dose of study.

         12. Used Depo-Provera® or levonorgestrel implant within 90 days prior to the first dose
             and throughout the study.

         13. Participation in another clinical trial within 28 days prior to the first dose of the
             study.

         14. Had a clinically significant illness during the 4 weeks prior to check-in on Day -1
             of Period 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Tricta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ApoPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferriprox®</keyword>
  <keyword>LI</keyword>
  <keyword>DFP</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>Healthy Volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deferiprone</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
